Literature DB >> 17533522

Expression of interferon-gamma and interleukin-4 production in CD4+ T cells in patients with chronic heart failure.

Takashi Fukunaga1, Hirofumi Soejima, Atsushi Irie, Koichi Sugamura, Yoko Oe, Tomoko Tanaka, Sunao Kojima, Tomohiro Sakamoto, Michihiro Yoshimura, Yasuharu Nishimura, Hisao Ogawa.   

Abstract

The prevalence of inflammation is high among patients with chronic heart failure (CHF). Reduced ejection fraction was associated with frequency of CD4(+) T cells of leukocytes. Therefore, we investigated inflammatory cytokines of expression markers in CD4(+) T cells in patients with CHF. Blood samples were obtained from 103 patients with CHF, from 83 patients with stable angina (SA), and from 57 controls. Interferon-gamma (IFN-gamma)-positive CD4(+) T cells and interleukin-4 (IL-4)-positive CD4(+) T cells were analyzed using 3-color flow cytometry. The frequency (%) of IFN-gamma-positive CD4(+) T cells increased in patients with CHF compared with those with SA and controls (CHF: 28.3 +/- 13.8, SA: 23.50 +/- 10.38, controls: 19.00 +/- 7.45, P < 0.001). There was no significant difference in the frequency of IL-4-positive CD4(+) T cells among the three groups. The frequencies of CD4(+) T cells that stained for IFN-gamma decreased from 32.37% +/- 16.40% on admission to 26.91% +/- 12.53% after 2 weeks in 26 patients with CHF. B-type natriuretic peptide (pg/ml) and high-sensitivity C-reactive protein (mg/dl) levels decreased from 251.7 +/- 150.4 and 0.64 +/- 0.78 on admission to 208.2 +/- 166.4 and 0.36 +/- 0.34 after 2 weeks in the 26 patients with CHF. We have demonstrated expression of IFN-gamma production of CD4(+) T cells during CHF. Prevention of unwanted T cell activation could represent a new target in the treatment of CHF.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533522     DOI: 10.1007/s00380-006-0955-8

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  28 in total

1.  Neurohormonal activation rapidly decreases after intravenous therapy with diuretics and vasodilators for class IV heart failure.

Authors:  Wendy Johnson; Torbjørn Omland; Christian Hall; Caroline Lucas; Ole L Myking; Caroline Collins; Marc Pfeffer; Jean-Lucien Rouleau; Lynne W Stevenson
Journal:  J Am Coll Cardiol       Date:  2002-05-15       Impact factor: 24.094

2.  Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.

Authors:  B Levine; J Kalman; L Mayer; H M Fillit; M Packer
Journal:  N Engl J Med       Date:  1990-07-26       Impact factor: 91.245

3.  Increased productivity of tumor necrosis factor-alpha in helper T cells in patients with systolic heart failure.

Authors:  Shinji Satoh; Jun-Ichi Oyama; Nobuhiro Suematsu; Toshiaki Kadokami; Nobuo Shimoyama; Masaaki Okutsu; Takeshi Inoue; Masahiro Sugano; Naoki Makino
Journal:  Int J Cardiol       Date:  2005-11-04       Impact factor: 4.164

4.  Myocardial expression of CC- and CXC-chemokines and their receptors in human end-stage heart failure.

Authors:  J K Damås; H G Eiken; E Oie; V Bjerkeli; A Yndestad; T Ueland; T Tonnessen; O R Geiran; H Aass; S Simonsen; G Christensen; S S Froland; H Attramadal; L Gullestad; P Aukrust
Journal:  Cardiovasc Res       Date:  2000-09       Impact factor: 10.787

5.  Serum erythropoietin in heart failure patients treated with ACE-inhibitors or AT(1) antagonists.

Authors:  B Chatterjee; U E Nydegger; P Mohacsi
Journal:  Eur J Heart Fail       Date:  2000-12       Impact factor: 15.534

6.  Elevated circulating levels of C-C chemokines in patients with congestive heart failure.

Authors:  P Aukrust; T Ueland; F Müller; A K Andreassen; I Nordøy; H Aas; J Kjekshus; S Simonsen; S S Frøland; L Gullestad
Journal:  Circulation       Date:  1998-03-31       Impact factor: 29.690

7.  Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system.

Authors:  Koichi Setsuta; Yoshihiko Seino; Takeshi Ogawa; Toshiaki Ohtsuka; Kohji Seimiya; Teruo Takano
Journal:  Circ J       Date:  2004-08       Impact factor: 2.993

8.  Circulating interleukin-6 family cytokines and their receptors in patients with congestive heart failure.

Authors:  Hisao Hirota; Masahiro Izumi; Tomoyuki Hamaguchi; Shoko Sugiyama; Eiki Murakami; Keita Kunisada; Yasushi Fujio; Yuichi Oshima; Yoshikazu Nakaoka; Keiko Yamauchi-Takihara
Journal:  Heart Vessels       Date:  2004-09       Impact factor: 2.037

9.  The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor beta.

Authors:  D J Pinsky; B Cai; X Yang; C Rodriguez; R R Sciacca; P J Cannon
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

10.  Enhanced expression of inflammatory cytokines and activation markers in T-cells from patients with chronic heart failure.

Authors:  Arne Yndestad; Are M Holm; Fredrik Müller; Svein Simonsen; Stig S Frøland; Lars Gullestad; Pål Aukrust
Journal:  Cardiovasc Res       Date:  2003-10-15       Impact factor: 10.787

View more
  19 in total

1.  Plasma levels of tumor necrosis factor-alpha and its receptors in patients with mitral stenosis and sinus rhythm undergoing percutaneous balloon valvuloplasty.

Authors:  Kumral Ergun Cagli; Dursun Aras; Serkan Topaloglu; Bilal Geyik; Selime Ayaz; Goksel Cagirci; Halil Lutfi Kisacik; Sule Korkmaz
Journal:  Heart Vessels       Date:  2010-03-26       Impact factor: 2.037

Review 2.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

3.  Serum concentrations of interleukin-4 and interferon-gamma in relation to severe left ventricular dysfunction in patients with acute myocardial infarction undergoing percutaneous coronary intervention.

Authors:  Janusz Szkodzinski; Bartosz Hudzik; Marcin Osuch; Wojciech Romanowski; Bozena Szygula-Jurkiewicz; Lech Polonski; Barbara Zubelewicz-Szkodzinska
Journal:  Heart Vessels       Date:  2010-12-03       Impact factor: 2.037

4.  Plasma levels of sRANKL and OPG are associated with atherogenic cytokines in patients with intermediate cardiovascular risk.

Authors:  Dorette Raaz-Schrauder; Michael G Schrauder; Christian Stumpf; Piotr Lewczuk; Tobias Kilian; Barbara Dietel; Christoph D Garlichs; Christian Schlundt; Stephan Achenbach; Lutz Klinghammer
Journal:  Heart Vessels       Date:  2017-05-31       Impact factor: 2.037

5.  Interleukin-2 enhances the cytotoxic activity of circulating natural killer cells in patients with chronic heart failure.

Authors:  Heng-Chen Yao; Shu-Qin Liu; Ke Yu; Min Zhou; Le-Xin Wang
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

6.  Interleukin-6 is a stronger prognostic predictor than high-sensitive C-reactive protein in patients with chronic stable heart failure.

Authors:  Borut Jug; Barbara Guzic Salobir; Nina Vene; Miran Sebestjen; Miso Sabovic; Irena Keber
Journal:  Heart Vessels       Date:  2009-07-22       Impact factor: 2.037

7.  Systemic inflammation in nonischemic dilated cardiomyopathy.

Authors:  Luisa De Gennaro; Natale Daniele Brunetti; Andrea Cuculo; Pier Luigi Pellegrino; Matteo Di Biase
Journal:  Heart Vessels       Date:  2008-11-27       Impact factor: 2.037

8.  The synergistic combined effect of anemia with high plasma levels of B-type natriuretic peptide significantly predicts an enhanced risk for major adverse cardiac events.

Authors:  Hirofumi Ueno; Masafumi Nakayama; Sunao Kojima; Kenichi Kusuhara; Yasuhiro Nagayoshi; Megumi Yamamuro; Tsunenori Nishijima; Hiroki Usuku; Kouichi Kaikita; Hitoshi Sumida; Hiroshige Yamabe; Seigo Sugiyama; Michihiro Yoshimura; Hisao Ogawa
Journal:  Heart Vessels       Date:  2008-07-23       Impact factor: 2.037

9.  Chronic systemic inflammation accompanies impaired ventricular diastolic function, detected by Doppler imaging, in patients with newly diagnosed systolic heart failure (Hellenic Heart Failure Study).

Authors:  Christina Chrysohoou; Christos Pitsavos; John Barbetseas; Iason Kotroyiannis; Stella Brili; Karmen Vasiliadou; Lambros Papadimitriou; Christodoulos Stefanadis
Journal:  Heart Vessels       Date:  2009-01-23       Impact factor: 2.037

10.  Insulin receptor substrates differentially exacerbate insulin-mediated left ventricular remodeling.

Authors:  Christian Riehle; Eric T Weatherford; Adam R Wende; Bharat P Jaishy; Alec W Seei; Nicholas S McCarty; Monika Rech; Qian Shi; Gopireddy R Reddy; William J Kutschke; Karen Oliveira; Karla Maria Pires; Joshua C Anderson; Nikolaos A Diakos; Robert M Weiss; Morris F White; Stavros G Drakos; Yang K Xiang; E Dale Abel
Journal:  JCI Insight       Date:  2020-03-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.